OBJECTIVE: This study was designed to explore the efficacy of budesonide (BUD) in preventing and treating bronchopulmonary dysplasia (BPD) in premature infants and its effect on pulmonary function. METHODS: A total of 94 premature infants with BPD who were born in our hospital were selected as the research subjects and divided into the control group (47 cases) for routine treatment and the research group (47 cases) for BUD therapy on the basis of routine treatment according to the random number table method. The incidence of BPD and the time of oxygen inhalation, ventilator ventilation, extubation and hospitalization were recorded in the two groups. In addition, arterial blood gas indexes (arterial oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)), inflammatory response indicators (interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF-α)), pulmonary function indexes (the ratio of time taken to reach peak expiratory flow to total expiratory time (TPTEF/TE), the ratio of peak expiratory volume to total expiratory volume (VPEF/VE), tidal expiratory flow at 25%/50%/75% remaining tidal volume (TEF25, TEF50, TEF75), and the incidence of complications were observed and compared. RESULTS: After treatment, SaO2 and PaO2 increased in both groups, and their values in the research group were higher than those in the control group; PaCO2 decreased in both groups, and the PaCO2 in the research group was lower than that in the control group (P<0.05). The post-treatment TNF-α, IL-6 and IL-8 levels decreased in both groups, and their levels in the research group were lower than those in the control group (all P<0.001). TPTEE/TE, VPEF/VE, TEF25, TEF50 and TEF75 increased in both groups after treatment, and their values in the research group were higher than those in the control group (all P<0.01). The research group required shorter oxygen inhalation time, ventilator ventilation time, time to extubation and hospitalization time than the control group (all P<0.001). The incidence of BPD and other complications in the research group were lower than that in the control group (8.51%, 6.38% vs. 23.40%, 21.28%; P=0.049, 0.036). CONCLUSION: BUD is effective in the prevention and treatment of BPD in premature infants, which can effectively reduce the incidence of BPD and other complications, improve blood gas indexes, reduce inflammatory reactions and promotes good pulmonary function in children. AJTR
OBJECTIVE: This study was designed to explore the efficacy of budesonide (BUD) in preventing and treating bronchopulmonary dysplasia (BPD) in premature infants and its effect on pulmonary function. METHODS: A total of 94 premature infants with BPD who were born in our hospital were selected as the research subjects and divided into the control group (47 cases) for routine treatment and the research group (47 cases) for BUD therapy on the basis of routine treatment according to the random number table method. The incidence of BPD and the time of oxygen inhalation, ventilator ventilation, extubation and hospitalization were recorded in the two groups. In addition, arterial blood gas indexes (arterial oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)), inflammatory response indicators (interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF-α)), pulmonary function indexes (the ratio of time taken to reach peak expiratory flow to total expiratory time (TPTEF/TE), the ratio of peak expiratory volume to total expiratory volume (VPEF/VE), tidal expiratory flow at 25%/50%/75% remaining tidal volume (TEF25, TEF50, TEF75), and the incidence of complications were observed and compared. RESULTS: After treatment, SaO2 and PaO2 increased in both groups, and their values in the research group were higher than those in the control group; PaCO2 decreased in both groups, and the PaCO2 in the research group was lower than that in the control group (P<0.05). The post-treatment TNF-α, IL-6 and IL-8 levels decreased in both groups, and their levels in the research group were lower than those in the control group (all P<0.001). TPTEE/TE, VPEF/VE, TEF25, TEF50 and TEF75 increased in both groups after treatment, and their values in the research group were higher than those in the control group (all P<0.01). The research group required shorter oxygen inhalation time, ventilator ventilation time, time to extubation and hospitalization time than the control group (all P<0.001). The incidence of BPD and other complications in the research group were lower than that in the control group (8.51%, 6.38% vs. 23.40%, 21.28%; P=0.049, 0.036). CONCLUSION:BUD is effective in the prevention and treatment of BPD in premature infants, which can effectively reduce the incidence of BPD and other complications, improve blood gas indexes, reduce inflammatory reactions and promotes good pulmonary function in children. AJTR
Authors: Kamini Raghuram; Michael Dunn; Krista Jangaard; Maureen Reilly; Elizabeth Asztalos; Edmond Kelly; Michael Vincer; Vibhuti Shah Journal: BMC Pediatr Date: 2018-05-07 Impact factor: 2.125
Authors: W Jackson; C P Hornik; J A Messina; K Guglielmo; A Watwe; G Delancy; A Valdez; T MacArthur; S Peter-Wohl; P B Smith; V N Tolia; M M Laughon Journal: J Perinatol Date: 2017-04-06 Impact factor: 3.225